|
Orthologous residues
|
|
Chk2 (human): T68‑p, Chk2 iso12 (human): T68‑p, Chk2 (mouse): T77‑p, Chk2 (rat): T76‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Disease tissue studied:
bone cancer
|
|
Relevant cell lines - cell types - tissues:
U2OS (bone cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
camptothecin
|
|
|
|
increase
|
|
|
|
camptothecin
|
Ctip (human)
|
|
no effect upon treatment-induced increase
|
Ctip shRNA or overexpression has no effect
|
|